Pierre Quartier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3242726/publications.pdf

Version: 2024-02-01

191 papers 15,231 citations

18482 62 h-index 19190 118 g-index

204 all docs

204 docs citations

times ranked

204

13382 citing authors

#	Article	IF	CITATIONS
1	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. New England Journal of Medicine, 2009, 360, 2416-2425.	27.0	754
2	Chronic Infantile Neurological Cutaneous and Articular Syndrome Is Caused by Mutations in CIAS1, a Gene Highly Expressed in Polymorphonuclear Cells and Chondrocytes. American Journal of Human Genetics, 2002, 71, 198-203.	6.2	718
3	Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406.	27.0	588
4	Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet, The, 2008, 372, 383-391.	13.7	486
5	A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Annals of the Rheumatic Diseases, 2011, 70, 747-754.	0.9	462
6	Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency. Nature Immunology, 2012, 13, $1178-1186$.	14.5	410
7	Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis and Rheumatism, 2010, 62, 2458-2466.	6.7	352
8	Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis and Rheumatism, 2003, 48, 1093-1101.	6.7	343
9	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
10	Autoimmunity in Wiskott-Aldrich Syndrome: Risk Factors, Clinical Features, and Outcome in a Single-Center Cohort of 55 Patients. Pediatrics, 2003, 111, e622-e627.	2.1	294
11	Detection of interferon alpha protein reveals differential levels and cellular sources in disease. Journal of Experimental Medicine, 2017, 214, 1547-1555.	8.5	288
12	Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet, The, 2001, 358, 1511-1513.	13.7	287
13	Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. Journal of Pediatrics, 1999, 134, 589-596.	1.8	282
14	Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117.	0.9	251
15	Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children. Annals of Intensive Care, 2020, 10, 69.	4.6	247
16	Longâ€term efficacy of the interleukinâ€1 receptor antagonist anakinra in ten patients with neonatalâ€onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis and Rheumatism, 2010, 62, 258-267.	6.7	239
17	Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clinical Immunology, 2004, 110, 22-29.	3.2	224
18	Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2017, 140, 1388-1393.e8.	2.9	222

#	Article	IF	CITATIONS
19	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Annals of the Rheumatic Diseases, 2015, 74, 799-805.	0.9	215
20	Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1792-1802.	6.7	204
21	Protein kinase D at the Golgi controls NLRP3 inflammasome activation. Journal of Experimental Medicine, 2017, 214, 2671-2693.	8.5	197
22	Mevalonate Kinase Deficiency: A Survey of 50 Patients. Pediatrics, 2011, 128, e152-e159.	2.1	195
23	EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Annals of the Rheumatic Diseases, 2010, 69, 790-797.	0.9	187
24	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030.	0.9	183
25	Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Annals of the Rheumatic Diseases, 2015, 74, 2043-2049.	0.9	180
26	Interleukin-1 Targeting Drugs in Familial Mediterranean Fever: A Case Series and a Review of the Literature. Seminars in Arthritis and Rheumatism, 2011, 41, 265-271.	3.4	178
27	A Large National Cohort of French Patients With Chronic Recurrent Multifocal Osteitis. Arthritis and Rheumatology, 2015, 67, 1128-1137.	5.6	178
28	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. Arthritis and Rheumatology, 2016, 68, 2795-2805.	5.6	168
29	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, The, 2016, 387, 671-678.	13.7	168
30	A phase II, multicenter, open″abel study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis and Rheumatism, 2012, 64, 557-567.	6.7	167
31	RNA recognition by human TLR8 can lead to autoimmune inflammation. Journal of Experimental Medicine, 2013, 210, 2903-2919.	8.5	167
32	Lupus-Prone Mice Have an Abnormal Response to Thioglycolate and an Impaired Clearance of Apoptotic Cells. Journal of Immunology, 2003, 170, 3223-3232.	0.8	165
33	Type I interferon-mediated autoinflammation due to DNase II deficiency. Nature Communications, 2017, 8, 2176.	12.8	164
34	Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease. Journal of Clinical Immunology, 2017, 37, 123-132.	3.8	163
35	Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophagesin vitro. European Journal of Immunology, 2005, 35, 252-260.	2.9	155
36	Analysis of TCR, $pT\hat{l}_{\pm}$, and RAG-1 in T-acute lymphoblastic leukemias improves understanding of early human T-lymphoid lineage commitment. Blood, 2003, 101, 2693-2703.	1.4	152

#	Article	IF	CITATIONS
37	<i>HLA-DRB1*11</i> i>and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	7.1	139
38	Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2002, 117, 965-972.	2.5	128
39	Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. British Journal of Haematology, 2001, 115, 112-118.	2.5	125
40	Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon-Î ³ . Rheumatology, 2015, 54, 1507-1517.	1.9	125
41	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	5.6	120
42	Evaluation of a peer support group therapy for HIV-infected adolescents. Aids, 2005, 19, 1501-1508.	2.2	112
43	Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology, 2012, 51, 1855-1859.	1.9	112
44	Allogeneic Bone Marrow Transplantation in Mevalonic Aciduria. New England Journal of Medicine, 2007, 356, 2700-2703.	27.0	110
45	ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Annals of the Rheumatic Diseases, 2018, 77, 1003-1011.	0.9	110
46	The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2013, 72, 686-693.	0.9	109
47	Enteroviral Meningoencephalitis after Antiâ€CD20 (Rituximab) Treatment. Clinical Infectious Diseases, 2003, 36, e47-e49.	5.8	106
48	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
49	Results from a multicentre international registry of familial Mediterranean fever: impact of environment on the expression of a monogenic disease in children. Annals of the Rheumatic Diseases, 2014, 73, 662-667.	0.9	92
50	Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis). Pediatric Rheumatology, 2014, 12, 18.	2.1	85
51	Abatacept in the Treatment of Severe, Longstanding, and Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2015, 42, 706-711.	2.0	85
52	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	3.4	84
53	The emerging role of interleukinâ \in l \hat{l}^2 in autoinflammatory diseases. Arthritis and Rheumatism, 2011, 63, 314-324.	6.7	82
54	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.9	79

#	Article	IF	CITATIONS
55	Safety and Efficacy of Rituximab in Severe Juvenile Dermatomyositis: Results from 9 Patients from the French Autoimmunity and Rituximab Registry. Journal of Rheumatology, 2011, 38, 1436-1440.	2.0	77
56	Early Recombinant Human Growth Hormone Treatment in Glucocorticoid-Treated Children with Juvenile Idiopathic Arthritis: A 3-Year Randomized Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2567-2573.	3.6	75
57	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor–Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. Arthritis Care and Research, 2017, 69, 578-586.	3.4	75
58	Anakinra in children and adults with Still's disease. Rheumatology, 2019, 58, vi9-vi22.	1.9	75
59	ENTEROVIRAL MENINGOENCEPHALITIS IN X-LINKED AGAMMAGLOBULINEMIA: INTENSIVE IMMUNOGLOBULIN THERAPY AND SEQUENTIAL VIRAL DETECTION IN CEREBROSPINAL FLUID BY POLYMERASE CHAIN REACTION. Pediatric Infectious Disease Journal, 2000, 19, 1106-1108.	2.0	73
60	Abatacept improves healthâ€related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care and Research, 2010, 62, 1542-1551.	3.4	72
61	Immunological loss-of-function due to genetic gain-of-function in humans: autosomal dominance of the third kind. Current Opinion in Immunology, 2015, 32, 90-105.	5. 5	69
62	Development of the autoinflammatory disease damage index (ADDI). Annals of the Rheumatic Diseases, 2017, 76, 821-830.	0.9	68
63	Anti–tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. Epilepsia, 2016, 57, 956-966.	5.1	67
64	Morphologic and immunohistochemical characterization ofÂgranulomas in the nucleotide oligomerization domain 2–related disorders Blau syndrome and Crohn disease. Journal of Allergy and Clinical Immunology, 2012, 129, 1076-1084.	2.9	64
65	Mutation in the <i>SLC29A3</i> Gene: A New Cause of a Monogenic, Autoinflammatory Condition. Pediatrics, 2013, 131, e1308-e1313.	2.1	64
66	The incidence of clonal T-cell receptor rearrangements in B-cell precursor acute lymphoblastic leukemia varies with age and genotype. Blood, 2000, 96, 2254-2261.	1.4	63
67	Childhood-onset granulomatosis with polyangiitis and microscopic polyangiitis: systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2016, 11, 141.	2.7	62
68	Molecular Basis of a Selective C1s Deficiency Associated with Early Onset Multiple Autoimmune Diseases. Journal of Immunology, 2001, 166, 7612-7616.	0.8	61
69	LRBA deficiency with autoimmunity and early onset chronic erosive polyarthritis. Clinical Immunology, 2016, 168, 88-93.	3.2	57
70	Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clinical Immunology, 2018, 188, 52-57.	3.2	53
71	JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology, 2021, 60, 5801-5808.	1.9	52
72	Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opinion on Biological Therapy, 2019, 19, 477-490.	3.1	51

#	Article	IF	CITATIONS
73	Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology, 2010, 49, 1694-1698.	1.9	49
74	Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC Pharmacology & Expression (2013), 14, 40.	2.4	49
75	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	3.5	49
76	Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthritis followed in a French tertiary care pediatric rheumatology centre. Pediatric Rheumatology, 2018, 16, 21.	2.1	49
77	Brief Report: Childhoodâ€Onset Systemic Necrotizing Vasculitides: Longâ€Term Data From the French Vasculitis Study Group Registry. Arthritis and Rheumatology, 2015, 67, 1959-1965.	5.6	47
78	ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open, 2016, 2, e000236.	3.8	47
79	Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatology International, 2012, 32, 711-716.	3.0	45
80	Radiological cervical spine involvement in young adults with polyarticular juvenile idiopathic arthritis. Rheumatology, 2013, 52, 267-275.	1.9	45
81	Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i104-12.	0.7	45
82	Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis. Rheumatology, 2018, 57, 873-879.	1.9	44
83	Cataract surgery with primary intraocular lens implantation in children with uveitis: Long-term outcomes. Journal of Cataract and Refractive Surgery, 2011, 37, 1977-1983.	1.5	43
84	Biological treatment in systemic juvenile idiopathic arthritis: achievement of inactive disease or clinical remission on a first, second or third biological agent. RMD Open, 2015, 1, e000036-e000036.	3.8	42
85	Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case–control study from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 108-114.	5.8	42
86	Efficacy and safety of TNF $\hat{l}\pm$ antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine, 2009, 76, 24-27.	1.6	41
87	Severe cardiac involvement in children with systemic sclerosis and myositis. Journal of Rheumatology, 2002, 29, 1767-73.	2.0	40
88	Germ-line transcription and methylation status of the TCR-J \hat{l} ± locus in its accessible configuration. European Journal of Immunology, 1997, 27, 1619-1625.	2.9	38
89	Disease of the Year: Juvenile Idiopathic Arthritis-associated Uveitis—Classification and Diagnostic Approach. Ocular Immunology and Inflammation, 2014, 22, 56-63.	1.8	36
90	Haemopoietic stem-cell transplantation for juvenile chronic arthritis. Lancet, The, 1999, 353, 1885-1886.	13.7	34

#	Article	IF	Citations
91	Tolerance of efavirenz in children. Aids, 2001, 15, 241-243.	2.2	34
92	Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement—A new target for lupus treatment. Science Advances, 2019, 5, eaav9019.	10.3	34
93	Ocular threat in juvenile idiopathic arthritis. Joint Bone Spine, 2009, 76, 383-388.	1.6	33
94	Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity ScoreÂCutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1966-1975.	5.6	33
95	Primary Cytomegalovirus Infection, Atypical Kawasaki Disease, and Coronary Aneurysms in 2 Infants. Clinical Infectious Diseases, 2005, 41, e53-e56.	5.8	32
96	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmunity Reviews, 2017, 16, 650-657.	5.8	32
97	A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever. Orphanet Journal of Rare Diseases, 2017, 12, 54.	2.7	32
98	Current treatments for juvenile idiopathic arthritis. Joint Bone Spine, 2010, 77, 511-516.	1.6	31
99	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clinical and Experimental Rheumatology, 2018, 36, 668-675.	0.8	31
100	The identification of <i>MAFB</i> mutations in eight patients with multicentric carpo–tarsal osteolysis supports genetic homogeneity but clinical variability. American Journal of Medical Genetics, Part A, 2013, 161, 3023-3029.	1.2	30
101	Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort. RMD Open, 2019, 5, e000933.	3.8	29
102	Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 128-135.	2.0	28
103	Inborn errors of metabolism underlying primary immunodeficiencies. Journal of Clinical Immunology, 2014, 34, 753-771.	3.8	27
104	In silico validation of the Autoinflammatory Disease Damage Index. Annals of the Rheumatic Diseases, 2018, 77, 1599-1605.	0.9	27
105	Juvenile Idiopathic Arthritis: Classification, Clinical Presentation and Current Treatments. Hormone Research, 2009, 72, 4-12.	1.8	26
106	The lung is involved in juvenile dermatomyositis. Pediatric Pulmonology, 2013, 48, 1016-1025.	2.0	26
107	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-1± signalling. Rheumatology, 2020, 59, 1927-1937.	1.9	26
108	Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT). Trials, 2021, 22, 689.	1.6	26

#	Article	IF	CITATIONS
109	Impact of juvenile idiopathic arthritis on quality of life during transition period at the era of biotherapies. Joint Bone Spine, 2016, 83, 69-74.	1.6	25
110	Uveitis Related to Juvenile Idiopathic Arthritis: Familial Cases and Possible Genetic Implication in the Pathogenesis. Ocular Immunology and Inflammation, 2010, 18, 172-177.	1.8	24
111	Musculoskeletal Symptoms in Patients With Cryopyrinâ€Associated Periodic Syndromes: A Large Database Study. Arthritis and Rheumatology, 2015, 67, 3027-3036.	5.6	24
112	Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. Journal of Ophthalmic Inflammation and Infection, 2011, 1, 133-136.	2.2	23
113	Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review. Journal of Rheumatology, 2018, 45, 425-429.	2.0	23
114	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‣abel, Randomized Study. Arthritis and Rheumatology, 2021, 73, 336-346.	5.6	23
115	Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges. Pediatric Rheumatology, 2018, 16, 5.	2.1	22
116	Long-term outcome of children with pediatric-onset cutaneous and visceral polyarteritis nodosa. Joint Bone Spine, 2015, 82, 251-257.	1.6	21
117	Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis. Rheumatology, 2016, 55, kev359.	1.9	21
118	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Openâ€Label, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
119	MRI assessment of tenosynovitis in children with juvenile idiopathic arthritis: inter- and intra-observer variability. Pediatric Radiology, 2013, 43, 796-802.	2.0	20
120	Validation of the French version of the Childhood Health Assessment Questionnaire (CHAQ) in juvenile idiopathic arthritis. Joint Bone Spine, 2002, 69, 468-481.	1.6	19
121	Improvements in growth parameters in children with juvenile idiopathic arthritis associated with the effect of methotrexate on disease activity. Joint Bone Spine, 2005, 72, 392-396.	1.6	19
122	Identification of germline monoallelic mutations in <i>IKZF2</i> in patients with immune dysregulation. Blood Advances, 2022, 6, 2444-2451.	5.2	18
123	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. Biology of Blood and Marrow Transplantation, 2013, 19, 666-669.	2.0	17
124	Initial presentation and outcome of pediatric-onset mixed connective tissue disease: A French multicenter retrospective study. Joint Bone Spine, 2016, 83, 369-371.	1.6	17
125	Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Sevenâ€Year Interim Results. Arthritis Care and Research, 2020, 72, 1420-1430.	3.4	17
126	Therapeutic advances in juvenile idiopathic arthritis - associated uveitis. Current Opinion in Ophthalmology, 2019, 30, 179-186.	2.9	16

#	Article	IF	CITATIONS
127	Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies. Journal of Clinical Immunology, 2021, 41, 603-609.	3.8	16
128	Infantile Onset Panniculitis with Uveitis and Systemic Granulomatosis: A New Clinicopathologic Entity. Journal of Pediatrics, 2007, 151, 707-709.	1.8	15
129	Lupus nephritis associated with complete C1s deficiency efficiently treated with rituximab: A case report. Arthritis Care and Research, 2010, 62, 1346-1350.	3.4	15
130	Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry. Autoimmunity Reviews, 2018, 17, 984-989.	5.8	15
131	The European network for care of children with paediatric rheumatic diseases: care across borders. Rheumatology, 2019, 58, 1188-1195.	1.9	15
132	Circulating Interferonâ€Î± Measured With a Highly Sensitive Assay as a Biomarker for Juvenile Inflammatory Myositis Activity: Comment on the Article by Mathian et al. Arthritis and Rheumatology, 2020, 72, 195-197.	5.6	15
133	Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology, 2020, 18, 19.	2.1	15
134	Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry. Journal of Rheumatology, 2022, 49, 398-407.	2.0	15
135	Sicca syndrome and salivary gland infiltration in children with autoimmune disorders: when can we diagnose Sjögren syndrome?. Clinical and Experimental Rheumatology, 2010, 28, 434-9.	0.8	15
136	Radiological Peripheral Involvement in a Cohort of Patients with Polyarticular Juvenile Idiopathic Arthritis at Adulthood. Journal of Rheumatology, 2013, 40, 520-527.	2.0	14
137	Realâ€World Experience and Impact of Canakinumab in Cryopyrinâ€Associated Periodic Syndrome: Results From a French Observational Study. Arthritis Care and Research, 2017, 69, 903-911.	3.4	14
138	Juvenile dermatomyositis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1457-1463.	1.8	13
139	From Diagnosis to Prognosis: Revisiting the Meaning of Muscle <i>ISG15</i> Overexpression in Juvenile Inflammatory Myopathies. Arthritis and Rheumatology, 2021, 73, 1044-1052.	5.6	13
140	Propionibacterium acnes Chest Infections in Patients with Chronic Granulomatous Disease: Case Reports. Clinical Infectious Diseases, 2002, 34, 853-854.	5.8	12
141	Severe Abdominal Manifestations in Juvenile Dermatomyositis. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 247-251.	1.8	12
142	Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1853-1857.	1.9	11
143	Comparative Tolerability of Treatments for Juvenile Idiopathic Arthritis. BioDrugs, 2000, 14, 159-183.	4.6	10
144	ANCA-Associated Glomerulonephritis in Systemic-Onset Juvenile Idiopathic Arthritis. American Journal of Kidney Diseases, 2012, 59, 439-443.	1.9	10

#	Article	IF	Citations
145	Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches. Journal of Clinical Medicine, 2021, 10, 2934.	2.4	10
146	Hyperphosphatemic Familial Tumoral Calcinosis With <i>Galnt3</i> Mutation: Transient Response to Antiâ€Interleukinâ€I Treatments. JBMR Plus, 2019, 3, e10185.	2.7	9
147	Inflammatory Bowel Disease in Children With Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 567-574.	2.0	9
148	Foveal Serous Retinal Detachment in Juvenile Idiopathic Arthritis-associated Uveitis. Ocular Immunology and Inflammation, 2016, 24, 386-391.	1.8	8
149	Chronic idiopathic musculoskeletal pain in youth: a qualitative study. Pediatric Rheumatology, 2019, 17, 86.	2.1	8
150	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clinical and Experimental Rheumatology, 2018, 36, 920-928.	0.8	8
151	AA amyloidosis complicating cryopyrin-associated periodic syndrome: a study of 86 cases including 23 French patients and systematic review. Rheumatology, 2022, 61, 4827-4834.	1.9	8
152	Evaluation of the efficiency of hydroxychloroquine in treating children with immune thrombocytopenia (ITP). American Journal of Hematology, 2017, 92, E79-E81.	4.1	7
153	Presentations and outcomes of juvenile dermatomyositis patients admitted to intensive care units. Rheumatology, 2017, 56, 1814-1816.	1.9	7
154	Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis. Seminars in Arthritis and Rheumatism, 2019, 48, 1014-1018.	3.4	7
155	Sustained remission after haploidentical bone marrow transplantation in a child with refractory systemic juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 27.	2.1	7
156	Validation de la version française du Childhood Health Assessment Questionnaire (CHAQ) dans les arthrites juvÃ@niles idiopathiques. Revue Du Rhumatisme (Edition Française), 2002, 69, 898-914.	0.0	6
157	Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. Open Access Rheumatology: Research and Reviews, 2011, 3, 9.	1.6	6
158	Systemic Juvenile Idiopathic Arthritis/Pediatric Still's Disease, a Syndrome but Several Clinical Forms: Recent Therapeutic Approaches. Journal of Clinical Medicine, 2022, 11, 1357.	2.4	6
159	Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4578-4587.	3.6	5
160	Inhibition of IFNÎ \pm secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology. Rheumatology, 2020, 59, 1171-1174.	1.9	5
161	Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNI³) Monoclonal Antibody. Blood, 2021, 138, 2058-2058.	1.4	5
162	A4: Efficacy and Safety of Tocilizumab in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From CHERISH. Arthritis and Rheumatology, 2014, 66, S5-S6.	5.6	4

#	Article	IF	CITATIONS
163	Choice of biologic drug among children with juvenile idiopathic arthritis. Rheumatology, 2016, 55, 1534-1535.	1.9	4
164	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 898-906.	2.0	4
165	A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency. Journal of Clinical Immunology, 2019, 39, 702-712.	3.8	3
166	Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab. Journal of Clinical Rheumatology, 2019, 25, e40-e42.	0.9	3
167	Tocilizumab in patients with juvenile idiopathic arthritis-associated uveitis. Lancet Rheumatology, The, 2020, 2, e122-e123.	3.9	3
168	Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 1073-1081.	2.0	3
169	Do we need the PFAPA syndrome in adults with non-monogenic periodic fevers?. Annals of the Rheumatic Diseases, 2019, , annrheumdis-2019-216827.	0.9	3
170	A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report. Pediatric Rheumatology, 2021, 19, 168.	2.1	3
171	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 26-34.	0.8	3
172	Immunodeficiency and genetic conditions that cause arthritis in childhood. Current Rheumatology Reports, 2002, 4, 483-493.	4.7	2
173	FRI0549â€SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY. , 2019, , .		2
174	Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab – a real-world experience. Seminars in Arthritis and Rheumatism, 2020, 50, 744-748.	3.4	2
175	Human Papilloma Virus Vaccination in Patients with Rheumatic Diseases in France: A Study of Vaccination Coverage and Drivers of Vaccination. Journal of Clinical Medicine, 2022, 11, 4137.	2.4	2
176	Actualités thérapeutiques des arthrites juvéniles idiopathiques. Revue Du Rhumatisme (Edition) Tj ETQq0 (0 0 rgBT /0	Overlock 10 T
177	OP0055â€EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
178	Comment on: Monogenic mimics of Behçet's disease in the young. Rheumatology, 2020, 59, e109-e111.	1.9	1
179	Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice. Pediatric Rheumatology, 2021, 19, 139.	2.1	1
180	L'amélioration des paramÃ"tres de la croissance staturopondérale est associée à la réponse au traitement par le méthotrexate chez les enfants atteints d'arthrite juvénile idiopathique. Revue Du Rhumatisme (Edition Francaise), 2005, 72, 807-812.	0.0	0

#	Article	IF	CITATIONS
181	Share – Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	2.1	0
182	A152: Safety and Effectiveness of Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis Aged 2 to 4 Years. Arthritis and Rheumatology, 2014, 66, S196-S197.	5.6	0
183	Genetic association with articular damage in patients with juvenile idiopathic arthritis (JIA). Pediatric Rheumatology, 2014, 12, .	2.1	0
184	Étude randomisée en double insu testant l'anticorps anti-TNF alpha adalimumab contre placebo dans l'uvéite de l'arthrite juvénile idiopathique (Étude ADJUVITE). Revue Du Rhumatisme (Edition Franca 2016, 83, A115.	ai se))	0
185	Évolution à long terme des enfants atteints de forme pédiatrique de périartérite noueuse cutanée et viscérale. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 194-200.	0.0	O
186	Impact de l'arthrite juvénile idiopathique sur la qualité de vie pendant la période de transition à l'Ã adulte à l'ère des biothérapies. Revue Du Rhumatisme (Edition Francaise), 2016, 83, 281-286.	‡ge 9.0	0
187	The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 195-201.	3.0	O
188	The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 379-386.	3.0	0
189	AB1071â€AUTO-IMMUNE AND INFLAMMATORY DISEASES IN CHILDREN WITH SICKLE CELL DISEASE: DIAGNOS' AND THERAPEUTIC ISSUES. , 2019, , .	TIC	O
190	Pourquoi le clinicien est-il en difficulté devant l'adolescent présentant une douleur musculo-squelettique chronique fonctionnelle ? Une étude qualitative. Perspectives Psy, 2021, 60, 235-242.	0.1	0
191	Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. Rheumatology, 2022, , .	1.9	0